Bio-FD&C Co Ltd

The company maintains a strong liquidity position with KRW 10.75 billion in cash and equivalents, representing 14.7% of total assets. With a current ratio of 17.06, the firm has substantial short-term liquidity relative to its liabilities. The debt-to-equity ratio of 0.01 indicates minimal leverage, and long-term debt is only 0.5% of total liabilities. Free cash flow of KRW 7.19 billion supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity of 9.55% and return on assets of 9.08%, both exceeding the median for the Pharmaceuticals industry. Operating income of KRW 6.25 billion and net income of KRW 6.67 billion reflect strong margins, with gross profit at 67.1% of revenue. These returns suggest efficient asset utilization and cost control. The company operates as a single business segment, with no disclosed geographic revenue breakdown. All operations are based in South Korea, indicating high revenue concentration in one region. This lack of diversification may expose the firm to regional economic or regulatory risks. Recent financial performance shows a revenue of KRW 19.18 billion, with no historical data provided for growth analysis. Analysts have assigned a strong buy rating with a mean price target of KRW 19,100, suggesting confidence in the company's near-term prospects. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued additional shares recently, and there is no indication of near-term dilution pressure. The absence of significant debt or equity issuance suggests a stable capital structure. No recent filings or transcripts were provided in the input data to identify specific events or strategic developments. The company's operations and financials appear to be stable, with no disclosed material changes in the latest available data.